A genetic algorithm for structure-based de novo design
- PMID: 11918076
- DOI: 10.1023/a:1014389729000
A genetic algorithm for structure-based de novo design
Abstract
Genetic algorithms have properties which make them attractive in de novo drug design. Like other de novo design programs, genetic algorithms require a method to reduce the enormous search space of possible compounds. Most often this is done using information from known ligands. We have developed the ADAPT program, a genetic algorithm which uses molecular interactions evaluated with docking calculations as a fitness function to reduce the search space. ADAPT does not require information about known ligands. The program takes an initial set of compounds and iteratively builds new compounds based on the fitness scores of the previous set of compounds. We describe the particulars of the ADAPT algorithm and its application to three well-studied target systems. We also show that the strategies of enhanced local sampling and re-introducing diversity to the compound population during the design cycle provide better results than conventional genetic algorithm protocols.
Similar articles
-
LigMerge: a fast algorithm to generate models of novel potential ligands from sets of known binders.Chem Biol Drug Des. 2012 Sep;80(3):358-65. doi: 10.1111/j.1747-0285.2012.01414.x. Epub 2012 Jun 27. Chem Biol Drug Des. 2012. PMID: 22594624 Free PMC article.
-
A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.Proteins. 2004 Feb 15;54(3):526-33. doi: 10.1002/prot.10599. Proteins. 2004. PMID: 14748000
-
Synthesis, HIV-1 RT inhibitory, antibacterial, antifungal and binding mode studies of some novel N-substituted 5-benzylidine-2,4-thiazolidinediones.Daru. 2015 Jan 24;23(1):6. doi: 10.1186/s40199-014-0086-1. Daru. 2015. PMID: 25617150 Free PMC article.
-
Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors.Mem Inst Oswaldo Cruz. 2015 Nov;110(7):847-64. doi: 10.1590/0074-02760150239. Mem Inst Oswaldo Cruz. 2015. PMID: 26560977 Free PMC article. Review.
-
Development of nonnucleoside HIV reverse transcriptase inhibitors.Methods Enzymol. 1996;275:440-72. doi: 10.1016/s0076-6879(96)75026-7. Methods Enzymol. 1996. PMID: 9026654 Review. No abstract available.
Cited by
-
VitAL: Viterbi algorithm for de novo peptide design.PLoS One. 2010 Jun 2;5(6):e10926. doi: 10.1371/journal.pone.0010926. PLoS One. 2010. PMID: 20532195 Free PMC article.
-
Design of SARS-CoV-2 Main Protease Inhibitors Using Artificial Intelligence and Molecular Dynamic Simulations.Molecules. 2022 Jun 22;27(13):4020. doi: 10.3390/molecules27134020. Molecules. 2022. PMID: 35807268 Free PMC article.
-
Evolutionary design of molecules based on deep learning and a genetic algorithm.Sci Rep. 2021 Aug 27;11(1):17304. doi: 10.1038/s41598-021-96812-8. Sci Rep. 2021. PMID: 34453086 Free PMC article.
-
Advances in de Novo Drug Design: From Conventional to Machine Learning Methods.Int J Mol Sci. 2021 Feb 7;22(4):1676. doi: 10.3390/ijms22041676. Int J Mol Sci. 2021. PMID: 33562347 Free PMC article. Review.
-
Augmenting genetic algorithms with machine learning for inverse molecular design.Chem Sci. 2024 Sep 11;15(38):15522-39. doi: 10.1039/d4sc02934h. Online ahead of print. Chem Sci. 2024. PMID: 39296997 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources